Paradigm Biopharmaceuticals Limited (ASX: PAR) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Paradigm Biopharmaceuticals Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Paradigm Biopharmaceuticals Limited (ASX: PAR)
Latest News
Share Gainers
Why Paradigm, Pilbara Minerals, Qantas, & ResMed shares are storming higher
Share Gainers
Why Paradigm, Resolute, ResMed, & Serko shares raced higher today
Share Market News
Is Paradigm the real deal blockbuster biotech?
Share Market News
Why the Polynovo share price is now up 24x in 5 years
Share Market News
The Orthocell share price is going nuts on claims of a blockbuster medical breakthrough
52-Week Highs
Why these ASX shares just stormed to 52-week highs
Share Market News
Mesoblast shares halted as it asks investors to tip in another $75 million
Share Market News
US congressman resigns over ASX insider trading penny stock scandal
Share Market News
5 small-cap shares I'm watching in FY 2020
Share Gainers
Why Nufarm, Paradigm, ResApp, & Zip Co shares charged higher today
Share Market News
Paradigm reports "ground-breaking" osteoarthritis discovery: Is it the real deal?
Share Market News
Is Paradigm Biopharmaceuticals the share market's next huge winner?
Frequently Asked Questions
-
No, Paradigm does not pay shareholder dividends at this time.
-
Paradigm Biopharmaceuticals Limited listed on the ASX on 19 August 2015.
PAR ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Ltd (ASX: PAR) is a late-stage drug development company researching drug repurposing. The company seeks to identify and transform existing molecules to develop effective treatments for conditions with limited treatment options. Currently, more than 30% of therapies approved or launched globally represent drugs approved for new indications, reformulations, or new combinations of existing drugs.
Paradigm's current commercial prospect is injectable pentosan polysulfate sodium (PPS, or brand name Zilosul®) in the treatment of osteoarthritis. PPS is FDA-approved and has a track record of treating inflammation including bladder condition cystitis and is used in the EU for preventing deep vein thrombosis. Paradigm has advanced to Phase 3 trial stage investigating PPS for osteoarthritis treatment. The company is based in Melbourne with offices in the US and Europe.
